EUCTR2018-002319-86-ES进行中(未招募)1 期
Dominantly Inherited Alzheimer Network - DIA
Fundació Clínic per a la Recerca Biomèdica0 个研究点目标入组 45 人开始时间: 2018年11月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Signature of informed consent by the participant and companion of the study before carrying out any procedure related to the study
- •2. Age = 18 years and the child of an individual affected (clinically or by tests) of genetic Alzheimer's disease in a pedigree with a known mutation causing genetic Alzheimer's disease.
- •3. Cognitively normal (Clinical dementia Rating scale, CDR = 0) or with cognitive impairment in mild phase (CDR 0.5 or 1).
- •4. The participant has identified two people who are not their blood siblings who can serve as companions to the study.
- •5. Sufficient knowledge of the Castilian language (equivalent to 6th grade of primary school).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. The participant has a medical or psychiatric illness that would interfere according to clinical criteria in the initial evaluation and / or follow-up evaluations.
- •2. The participant has an advanced cognitive impairment that requires admission to a long-term care center.
- •3. The recruitment of a subject with cognitive impairment must be pre-approved by the Coordinating Group of DIAN.
- •4. Women who are pregnant or breast-feeding or who have planned to become pregnant during the study period
研究者
相似试验
招募中
不适用
Establishment of dementia onset and progression model considering relevant high-risk genes after COVID-19 infection in dementia high-risk groupMental and behavioural disordersKCT0007688The Catholic University of Korea, Seoul St. Mary's Hospital65
进行中(未招募)
不适用
An observational study of factors influencing age of onset of Alzheimer’s disease and disease progressioNervous System DiseasesAlzheimer's diseaseISRCTN24454186lster University600
Unknown
不适用
Orientation in AD Patients: PET-MR StudyAlzheimer DiseaseMild Cognitive ImpairmentNCT03030365Assuta Medical Center30
招募中
不适用
Dominantly Inherited Alzheimer Network (DIAN)Alzheimer's DiseaseNCT00869817Washington University School of Medicine700
进行中(未招募)
1 期
The GLP-1 receptor agonist liraglutide can slow down the progression of Alzheimer’s diseaseMedDRA version: 14.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersAlzheimer's diseaseEUCTR2011-000794-31-DKDept. of Pharmacology
